MétaCan
Menu
Back to cohort
Record W4413734039 · doi:10.1016/j.euo.2025.07.011

Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma—An Observational Prospective Multicentre Diagnostic Test Cohort Study

2025· article· en· W4413734039 on OpenAlexaff
Saeed Dabestani, Nessn Azawi, Riccardo Campi, Petrus Järvinen, Harry Nísen, Umberto Capitanio, Tommy Kjærgaard Nielsen, Giuseppe Simone, Mark Rochester, Euan Green, Sergio Fernandéz‐Pello, Christopher Blick, Francesco Porpiglia, Alexandre Ingels, Siniša Bratulić, Alessandro Antonelli, A. Ari Hakimi, Michael A.S. Jewett, Börje Ljungberg, Bimal Bhindi, Lorenzo Marconi, Alexander Laird, Grant D. Stewart, Rajesh Nair, Lars Lund, Neil Barber, Viraj A. Master, Andrea Minervini, Jose A. Karam, Francesco Gatto, Axel Bex

Bibliographic record

VenueEuropean Urology Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicRenal cell carcinoma treatment
Canadian institutionsUniversity of CalgaryPrincess Margaret Cancer Centre
FundersNIHR Cambridge Biomedical Research CentreMedical Research CouncilLunds UniversitetEuropean CommissionHorizon 2020National Institute for Health and Care ResearchCancer Research UKScottish Government
KeywordsMedicineRenal cell carcinomaObservational studyInternal medicineUrineProspective cohort studyCohort studyOncologyCohort

Abstract

fetched live from OpenAlex

BACKGROUND AND OBJECTIVE: Nonmetastatic (M0) clear cell renal cell carcinoma (ccRCC) recurs in ∼20% of patients within 5 yr after surgery. With no biomarkers available, recurrence detection relies on radiological imaging. Urine glycosaminoglycan profiles (GAGomes) were previously associated with M0 ccRCC recurrence. We conducted an observational prospective multicentre diagnostic test cohort study to evaluate GAGomes for postsurgery recurrence detection in M0 ccRCC. METHODS: Postsurgical M0 ccRCC patients with a Leibovich score of ≥5 points were included. Follow-up imaging up to 18 mo assessed radiological recurrence (reference standard). Urine GAGomes were measured every 3 mo to compute a GAGome score (index test). Sensitivity and specificity to radiological recurrence were calculated. The lead time between the first positive GAGome score and radiological recurrence was estimated. Bayesian joint modelling estimated recurrence-free survival hazard ratio (HR). KEY FINDINGS AND LIMITATIONS: Of the 393 patients screened (January 2020 to November 2021), 134 met the inclusion criteria. The median follow-up was 16 mo (interquartile range [IQR]: 12-18) for those without recurrence. At the last follow-up visit, 16% had recurred. The GAGome score had 90% sensitivity (95% confidence interval [CI]: 62-100%) and 51% specificity (95% CI: 30-71%) to radiological recurrence. The positive and negative predictive values were 26% (95%CI: 4-46%) and 97% (95% CI: 87-100%), respectively. The median lead time was 4.2 mo (IQR: 1.6-6.4). A 10-point GAGome score increase was associated with an HR of 1.62 (95% high density interval: 1.11-2.30) for recurrence. The main limitation was short follow-up time. CONCLUSIONS AND CLINICAL IMPLICATIONS: GAGome score had very high sensitivity to ccRCC recurrence, resulting in a negative predictive value of 97%. External validation foreseen in the study design aims to confirm its utility to personalise follow-up for M0 ccRCC patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.023
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.282
Teacher spread0.261 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Urology OncologySame topicRenal cell carcinoma treatmentFrench-language works237,207